The anthracyclines: when good things go bad.
The anthracyclines: when good things go bad.
复制标题
蒽环类药物：当好事变坏时。
DOI：
10.1007/s12012-007-0017-1
复制
发表时间：
2007
影响因子：
3.2
通讯作者：
Sarvazyan,Narine
中科院分区：
文献类型：
--
作者：
Minotti,Giorgio;Sarvazyan,Narine
在靶向治疗的时代，近半个世纪前发现的蒽环类药物可能显得太老而不好。虽然原型蒽环类药物已经存在了很多年，但有大量的临床事实可以反驳它们的时代已经结束。这些药物继续在治疗许多形式的癌症中发挥无可争议的作用，包括血液恶性肿瘤和实体瘤。然而，不幸的是，它们的主要副作用仍然存在：在蒽环类药物的临床使用开始时变得明显的危及生命的心脏毒性。除了这个长期存在的问题，我们现在发现，新的联合疗法往往会导致比预期更高的心脏毒性发生率，好像新设计的药物使心脏更容易受到旧药物的影响。然而，总的来说，大量的临床证据表明，蒽环类药物太好了，不会过时。然而，如果它们作为单一药物或与其他有前途的新药联合给药时对心脏造成的伤害较小，它们看起来会好得多。心血管毒理学的这期特刊介绍了基于2006年10月20日至21日在风景优美的奥尔莫别墅（意大利科莫）举行的“蒽环类药物毒性国际研讨会：分子机制和临床相关性”的讲座和讨论的论文集。本次会议由药物科学系和衰老卓越中心共同主办，G。d'Annunzio大学医学院，Chieti（意大利）和Menarini基金会。我们感谢他们的专员在财政和后勤方面提供的特殊支持。该讲习班旨在使临床医生、公共卫生工作者、药理学家和实验室科学家聚集一堂
In the era of targeted therapy the anthracyclines, which were discovered almost half-century ago, may appear to be too old to be good. While it is certainly true that the prototypic anthracyclines have been around for many years, there are robust clinical facts to confute that their time is over. These drugs continue to play an undisputed role in the treatment of many forms of cancer, including hematological malignancies and solid tumors. Unfortunately, however, their main side-effect remains: a life-threatening cardiotoxicity which became apparent at the beginning of anthracyclines’ clinical use. In addition to this long-standing problem, we are now discovering that new combination therapies often cause a higher than expected incidence of cardiotoxicity, as if the newly designed drugs make the heart more vulnerable to the old one. Altogether, however, an overwhelming amount of clinical evidence suggests that anthracyclines are too good to be old. Yet, they would look much better if they caused less harm to the heart when administered as either single agents or in combination with otherwise promising new drugs. This special issue of Cardiovascular Toxicology introduces a collection of papers based on lectures and discussions at the ‘‘International Workshop on Anthracycline Cardiotoxicity: Molecular Mechanisms and Clinical Correlates,’’held on October 20–21, 2006 in the scenic environment of Villa Olmo (Como, Italy). The meeting was co-sponsored by the Department of Drug Sciences & Center of Excellence on Aging, G. d’Annunzio University School of Medicine, Chieti (Italy) and the Menarini Foundation. We are indebted to their commissionaires for exceptional support both financially and logistically. The Workshop was aimed at bringing clinicians, public health workers, pharmacologists and laboratory scientists together